Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06271369 · ClinicalTrials.gov registry record
Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study.
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 613
- Enrollment target
NCT06271369: Completed study, sponsored by Novartis Pharmaceuticals.
NCT06271369 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 613 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06271369 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 613 participants
- Enrollment target
Study Summary
This was a retrospective non-interventional cohort study design using the Centers for Medicare and Medicaid Services (CMS) 100% Medicare data (2015Q1-2020Q4). Eligible adult patients with r/r DLBCL who were treated with CAR-T therapy were identified from the CMS 100% Medicare data. Patients who received chimeric antigen receptor modified T cell (CAR-T) therapy were further classified into tisa-cel and axi-cel cohorts based on the type of CAR-T treatment received. The index date was defined as the date of tisa-cel or axi-cel therapy administration. Baseline period was defined as three months prior to the index date. Study period was defined from the index date to the end of health plan coverage based on insurance enrollment file or death, whichever occurred earlier.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 613 participants |
| Start Date | 2022-08-11 |
| Est. Completion | 2023-02-15 |
What the finished NCT06271369 record still lists
NCT06271369 is an observational study that tracks outcomes without assigning an intervention. The registered 613 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT06271369 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06271369 about?
NCT06271369 is a clinical study titled "Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study.". This was a retrospective non-interventional cohort study design using the Centers for Medicare and Medicaid Services (CMS) 100% Medicare data (2015Q1-2020Q4). Eligible adult patients with r/r DLBCL who were treated with CAR-T therapy were identified from the CMS 100% Medicare data. Patients who rec...
What is the current status of trial NCT06271369?
This trial is currently completed. The enrollment target is 613 participants. The study started on 2022-08-11. Estimated completion is 2023-02-15.
Who is sponsoring clinical trial NCT06271369?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01810913 · 613 participants · Phase 2
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
- NCT03821857 · 614 participants · Phase 4
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
- NCT05006716 · 614 participants · Phase 1
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
- NCT06170788 · 614 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI